PMID- 38038416
OWN - NLM
STAT- MEDLINE
DCOM- 20231204
LR  - 20231216
IS  - 1581-3207 (Electronic)
IS  - 1318-2099 (Print)
IS  - 1318-2099 (Linking)
VI  - 57
IP  - 4
DP  - 2023 Dec 1
TI  - Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable 
      and metastatic intrahepatic cholangiocarcinoma: a systematic review and 
      meta-analysis.
PG  - 419-429
LID - 10.2478/raon-2023-0059 [doi]
AB  - BACKGROUND: The outcome of systemic therapy (ST) for unresectable and metastatic 
      intrahepatic cholangiocarcinoma (iCCA) is poor. This study aims to further 
      evaluate the efficacy and safety of locoregional therapy combined with systemic 
      therapy (LRT + ST) compared with only ST in unresectable and metastatic iCCA by 
      performing a systematic literature review and meta-analysis. METHODS: A 
      comprehensive search was performed in PubMed, Web of Science, EMBASE, and the 
      Cochrane Library up to November 3, 2022. The primary outcome was overall survival 
      (OS), and the secondary outcomes were progression-free survival (PFS), objective 
      response rate (ORR), and adverse events (AEs). RESULTS: Ten retrospective cohort 
      studies with 3,791 unresectable or metastatic iCCA patients were enrolled in this 
      study, including 1,120 who received ablation, arterially directed therapy (ADT), 
      or external beam radiation therapy (EBRT) combined with ST. The meta-analysis 
      showed that the LRT + ST group had a better OS (HR = 0.51; 95% CI =0.41-0.64; p 
      value < 0.001), PFS (HR = 0.40, 95% CI = 0.22-0.71, p value = 0.002) and ORR (RR 
      = 1.68; 95% CI = 1.17-2.42; p value = 0.005). Subgroup analysis showed that both 
      ST combined with ADT (HR = 0.42, 95% CI = 0.31-0.56, p value < 0.001) and EBRT 
      (HR = 0.67, 95% CI = 0.63-0.72, p value < 0.001) could improve OS. Neutropenia, 
      thrombocytopenia, anemia, anorexia, and vomiting did not show significant 
      differences between the groups (p value > 0.05). CONCLUSIONS: Compared with only 
      ST, LRT + ST improved survival outcomes for unresectable and metastatic iCCA 
      patients without increasing severe AEs, which can further provide a basis for 
      guidelines.
CI  - (c) 2023 Mengqi Zhang et al., published by Sciendo.
FAU - Zhang, Mengqi
AU  - Zhang M
AD  - Department of Oncology, Key Laboratory of Cancer Molecular and Translational 
      Research, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 
      China.
FAU - Qi, Weiwei
AU  - Qi W
AD  - Department of Oncology, Key Laboratory of Cancer Molecular and Translational 
      Research, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 
      China.
FAU - Qiu, Xiaofei
AU  - Qiu X
AD  - Qingdao Municipal Center for Disease Control & Prevention, Qingdao Institute of 
      Preventive Medicine, Qingdao, Shandong, China.
FAU - Yu, Chunpeng
AU  - Yu C
AD  - Interventional Medical Center, The Affiliated Hospital of Qingdao University, 
      Qingdao, Shandong, China.
FAU - Qiu, Wensheng
AU  - Qiu W
AD  - Department of Oncology, Key Laboratory of Cancer Molecular and Translational 
      Research, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, 
      China.
FAU - Wang, Song
AU  - Wang S
AD  - Interventional Medical Center, The Affiliated Hospital of Qingdao University, 
      Qingdao, Shandong, China.
FAU - Qiu, Zhenkang
AU  - Qiu Z
AD  - Interventional Medical Center, The Affiliated Hospital of Qingdao University, 
      Qingdao, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20231130
PL  - Poland
TA  - Radiol Oncol
JT  - Radiology and oncology
JID - 9317213
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - *Cholangiocarcinoma/therapy
MH  - Progression-Free Survival
MH  - *Bile Duct Neoplasms/therapy
MH  - Bile Ducts, Intrahepatic
PMC - PMC10690746
OTO - NOTNLM
OT  - locoregional therapy
OT  - meta-analysis
OT  - systemic therapy
OT  - unresectable iCCA
EDAT- 2023/12/01 12:43
MHDA- 2023/12/04 12:42
PMCR- 2023/12/01
CRDT- 2023/12/01 08:53
PHST- 2023/06/01 00:00 [received]
PHST- 2023/09/18 00:00 [accepted]
PHST- 2023/12/04 12:42 [medline]
PHST- 2023/12/01 12:43 [pubmed]
PHST- 2023/12/01 08:53 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - raon-2023-0059 [pii]
AID - 10.2478/raon-2023-0059 [doi]
PST - epublish
SO  - Radiol Oncol. 2023 Nov 30;57(4):419-429. doi: 10.2478/raon-2023-0059. eCollection 
      2023 Dec 1.